首页>>蛋白研究>>抗体>>激肽原1重链抗体
激肽原1重链抗体
  • 产品货号：
    BN41262R
  • 中文名称：
    激肽原1重链抗体
  • 英文名称：
    Rabbit anti-Kininogen 1 Polyclonal antibody

  • 货号

    产品规格

    售价

    备注

  • BN41262R-100ul

    100ul

    ¥2360.00

    交叉反应：Human 推荐应用：IHC-P,IHC-F,IF,ELISA

  • BN41262R-200ul

    200ul

    ¥3490.00

    交叉反应：Human 推荐应用：IHC-P,IHC-F,IF,ELISA

英文名称Kininogen 1
中文名称激肽原1重链抗体
别    名HMW Kininogen Heavy Chain; HMW Kininogen; Kininogen-1 heavy chain; BDK; Kininogen 1; Kininogen1; Kininogen-1; KNG1; LMW; Low molecular weight growth promoting factor; Low molecular weight kininogen; Alpha-2-thiol proteinase inhibitor; Fitzgerald factor; High molecular weight kininogen; HMWK; HMWK heavy chain; Ile-Ser-Bradykinin; Kallidin I; Kallidin II; Kininogen 1; Kininogen 1 heavy chain; KNG; KNG1_HUMAN; Williams-Fitzgerald-Flaujeac factor.  
研究领域心血管  细胞生物  信号转导  生长因子和激素  细胞骨架  细胞外基质  
抗体来源Rabbit
克隆类型Polyclonal
交叉反应Human, 
产品应用ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量40/70kDa
细胞定位细胞外基质 分泌型蛋白 
性    状Liquid
浓    度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human Kininogen-1 heavy chain:281-356/644 
亚    型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMedPubMed
产品介绍This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009].

Function:
Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

Subcellular Location:
Secreted, extracellular space.

Tissue Specificity:
Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.

Post-translational modifications:
Bradykinin is released from kininogen by plasma kallikrein.
Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
Phosphorylation sites are present in the extracellular medium.
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.

Similarity:
Contains 3 cystatin kininogen-type domains.

SWISS:
P01042

Gene ID:
3827

Database links:

Entrez Gene: 3827 Human

Omim: 228960 Human

SwissProt: P01042 Human

Unigene: 77741 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.


















image.png